{"symbol":"REGN","fiscalQuarter":"Q2-2018","reportDate":"2018-08-02","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2018","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 7.0%","keyNumbers":[{"metric":"EPS","actual":"$5.45","expected":"N/A","surprise":"+13.06%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on innovation and expanding our product offerings."],"summary":"Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. They emphasized ongoing efforts to enhance product offerings."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance exceeded expectations, contributing to a 7% increase in stock price following the earnings report. The positive surprise indicates effective cost management or strong sales in certain areas, although no revenue figures were disclosed. Investors may view this as a sign of resilience and potential for future growth.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2018 earnings: EPS beat expectations. Stock up 7.0%. Full breakdown."}}